KING OF PRUSSIA - CSL Behring, a business unit of global biotechnology leader CSL, today announced the availability of a 10g prefilled syringe for Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid).

The Hizentra prefilled syringes provide people living with Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) the ability to elevate their treatment experience by eliminating the need to draw medication from vials. CSL Behring now has a wide range of prefilled syringe sizes to help meet the individual needs of people living with PI or CIDP including a 1g, 2g, 5g and 10g.

Hizentra offers the convenience of at-home infusions under the skin for individuals managing PI or CIDP. This eliminates the need to travel to an infusion center or locate a vein, which is a benefit for those who may have venous access issues. Hizentra is the first and only self-administered immunoglobulin treatment for CIDP maintenance.

'The availability of the 10g prefilled syringe is CSL Behring's latest development in helping the rare disease community effectively manage PI and CIDP, as some patients may require treatment at a higher volume,' said Bob Lojewski, Senior Vice President and General Manager, North America, CSL Behring. 'We understand how important flexibility and convenience are in treatment options for people managing these lifelong conditions, and milestones such as this continue to reinforce Our Promise to address the unmet needs of people living with rare diseases.'

The availability of a 10g prefilled syringe comes at a time when people living with PI and CIDP seek more convenient treatment options. According to a Harris Poll survey of 100 adults living with CIDP, 72% said that administering treatment at home is extremely/very important to them. In a separate survey of 52 people living with PI who have used both SCIg and intravenous immunoglobulin treatment (IVIg), almost 80% said they preferred SCIg over IVIg.

Those interested in learning more about treatment with Hizentra should discuss with their physicians.

About Primary Immunodeficiency (PI)

PI diseases are a group of more than 450 rare, chronic disorders in which part of the body's immune system is missing or malfunctioning. Patients with PI commonly have frequent infections, reoccurring infections, infections that won't go away or unusually severe infections. As a result, patients may face repeated courses of antibiotics or be hospitalized for treatment. Many people living with PI have missed school, work or time with family and friends due to their PI.

About Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

CIDP is a rare autoimmune disorder that affects the peripheral nerves (those outside the brain and spinal cord) and damages the protective covering of the nerves known as the myelin sheath. This may result in numbness or tingling, muscle weakness, fatigue and other symptoms. CIDP symptoms can worsen over time, leading to significant activity limitations and a decreased quality of life. CIDP can occur at any age and is more common in men than in women. Approximately 30% of CIDP patients progress to wheelchair dependence if not treated. The GBS|CIDP Foundation estimates that the incidence of new CIDP cases is as high as two in 100,000 people, with the accumulation of cases over time resulting in prevalence as high as nine in 100,000 in some areas.

About the CIDP Survey

The survey was conducted on behalf of CSL Behring of 100 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patients and 100 neurologists/neuromuscular specialists. The survey took place between February 27, 2023 and March 15, 2023. Patients were identified and recruited directly by treating physicians. Both patients and physicians were fully screened for eligibility. The survey qualification criteria for patients include being age 18+, residency in the U.S. and CIDP diagnosis. The survey qualification criteria for physicians include that they practice in the U.S., are duly licensed, are neurologists/neuromuscular specialists and regularly see at least one patient with CIDP.

About the PI Survey

The survey was conducted on behalf of CSL Behring between August 4 and September 22, 2021, among 104 PI patients that have ever received immune globulin treatment, including IVIg (n=65), SCIg in glass vials (n=65), and/or SCIg in PFS (n=33). All participants were U.S. residents over the age of 18.

About Hizentra

Registered in more than 60 countries, Hizentra is the most prescribed subcutaneous immunoglobulin for primary immunodeficiency (PI) in the U.S. It has a proven track record of safety, efficacy, and tolerability. Hizentra was first approved by the U.S. FDA in March 2010 for the treatment of patients with PI and was approved in March 2018 for the treatment of adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to prevent relapse of neuromuscular disability and impairment.

About CSL Behring

CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients' needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. We use three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continued innovation and continually refine ways in which products can address unmet medical needs and help patients lead full lives.

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. Our parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 32,000 people, and delivers its lifesaving therapies to people in more than 100 countries.

Contact:

Etanjalie Ayala

Tel: +1 610 297 1069

Email: etanjalie.ayala@cslbehring.com

(C) 2024 Electronic News Publishing, source ENP Newswire